Evidence map›Paper›PMID 41553715›Full record

ArticleAdvances in therapy2026

Correction to: Tiprelestat for Treatment of Hospitalized COVID-19: Results of the Double-Blind Randomized Placebo-Controlled COMCOVID Trial.

Ingmar Bergs, Stephan Budweiser, Hans-Heinrich Henneicke-von Zepelin, Hagen Kelm, Tom Bollmann, Johannes-Josef Tebbe, Stephan Sorichter, Stefan Lüth, Stephan Walterspacher, Henning Wege and 2 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Ingmar BergsDepartment of Pneumology and Intensive Care Medicine, RWTH Aachen University Hospital, Pauwelsstr. 30, 52074, Aachen, Germany. ibergs@ukaachen.de.
Stephan BudweiserDepartment of Internal Medicine III, RoMed Klinikum Rosenheim, Rosenheim, Germany.
Hans-Heinrich Henneicke-von Zepelintiakis Biotech AG, Kiel, Germany.ORCID http://orcid.org/0000-0001-5473-5887
Hagen KelmDepartment of Pneumology, Ruppin Hospital, Neuruppin, Germany.
Tom BollmannDepartment of Pneumology, Helios Hospital, Stralsund, Germany.
Johannes-Josef TebbeDepartment of Gastroenterology and Infectiology, Hospital Lippe, Medical School and University Medical Center OWL, Bielefeld University, Bielefeld, Germany.
Stephan SorichterDepartment of Pneumology and Respiratory Medicine, St. Josefskrankenhaus, Freiburg i.B., Germany.
Stefan LüthDepartment of Internal Medicine II, University Hospital, Brandenburg an der Havel, Germany.
Stephan WalterspacherDepartment Department of Pneumology, Medical Clinic, Hospital of Konstanz, Constance, Germany, and Witten/Herdecke University, Witten, Germany.
Henning WegeDepartment of General Internal Medicine, Oncology/Haematology, Gastroenterology and Infectiology, Hospital Esslingen, Esslingen, Germany.
Oliver Wiedowtiakis Biotech AG, Kiel, Germany.
Michael DreherDepartment of Pneumology and Intensive Care Medicine, RWTH Aachen University Hospital, Pauwelsstr. 30, 52074, Aachen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41553715
PMCPMC12999679

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.